Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
CAR T-cell manufacturing from naive/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Silvia Arcangeli, Camilla Bove, Claudia Mezzanotte, Barbara Camisa, Laura Falcone, Francesco Manfredi, Eugenia Bezzecchi, Rita El Khoury, Rossana Norata, Francesca Sanvito, Maurilio Ponzoni, Beatrice Greco, Marta A Moresco, Matteo G. Carrabba, Fabio Ciceri, Chiara Bonini, Attilio Bondanza, Monica Casucci |
Journal of Clinical Investigation | 2022 |
Knowns and Unknowns about CAR-T Cell Dysfunction
A Titov, Y Kaminskiy, I Ganeeva, E Zmievskaya, A Valiullina, A Rakhmatullina, A Petukhov, R Miftakhova, A Rizvanov, E Bulatov |
Cancers | 2022 |
Interaction of Immune and Cancer Cells
M Klink, I Szulc-Kielbik |
2022 | |
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
C Funk, S Wang, K Chen, A Waller, A Sharma, C Edgar, V Gupta, S Chandrakasan, J Zoine, A Fedanov, S Raikar, J Koff, C Flowers, S Coma, J Pachter, S Ravindranathan, H Spencer, M Shanmugam, E Waller |
Blood | 2022 |
Rapid manufacturing of non-activated potent CAR T cells
S Ghassemi, J Durgin, S Nunez-Cruz, J Patel, J Leferovich, M Pinzone, F Shen, K Cummins, G Plesa, V Cantu, S Reddy, F Bushman, S Gill, U ODoherty, R OConnor, M Milone |
Nature Biomedical Engineering | 2022 |
Understanding the Effects of Age and T-Cell Differentiation on COVID-19 Severity: Implicating a Fas/FasL-mediated Feed-Forward Controller of T-Cell Differentiation
A Leonardi, C Argyropoulos, A Hamdy, R Proenca |
Frontiers in immunology | 2022 |
The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
Y Fujiwara, T Kato, F Hasegawa, M Sunahara, Y Tsurumaki |
Pharmaceuticals (Basel, Switzerland) | 2022 |
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
P Shah, M Forget, M Frank, P Jiang, D Sakellariou-Thompson, L Federico, R Khairullah, C Neutzler, I Wistuba, C Chow, Y Long, J Fujimoto, S Lin, A Maitra, M Negrao, K Mitchell, A Weissferdt, A Vaporciyan, T Cascone, J Roth, J Zhang, B Sepesi, D Gibbons, J Heymach, C Haymaker, D McGrail, A Reuben, C Bernatchez |
Journal for ImmunoTherapy of Cancer | 2022 |
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Zhang C, He J, Liu L, Wang J, Wang S, Liu L, Ge J, Gao L, Gao L, Kong P, Liu Y, Liu J, Han Y, Zhang Y, Sun Z, Ye X, Yin W, Sersch M, Shen L, Cao WW, Zhang X |
Blood Cancer Journal | 2022 |
Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes
Knörck A, Schäfer G, Alansary D, Richter J, Thurner L, Hoth M, Schwarz EC |
Frontiers in immunology | 2022 |
HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity
Andrew Nguyen, Louisa Ho, Richard Hogg, Lan Chen, Scott R Walsh, Yonghong Wan |
Journal of Clinical Investigation | 2022 |
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.
Caël B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S, Poussard M, Godet Y, Angelot-Delettre F, Barisien C, Bésiers C, Adotevi O, Pouthier F, Garnache-Ottou F, Bôle-Richard E |
Cancers | 2022 |
Stem-like T cells and niches: Implications in human health and disease
Yi L, Yang L |
Frontiers in immunology | 2022 |
Super-Resolution Imaging of Fas/CD95 Reorganization Induced by Membrane-Bound Fas Ligand Reveals Nanoscale Clustering Upstream of FADD Recruitment
Frazzette N, Cruz AC, Wu X, Hammer JA, Lippincott-Schwartz J, Siegel RM, Sengupta P |
Cells | 2022 |
High-Intensity Aerobic Exercise Suppresses Cancer Growth by Regulating Skeletal Muscle-Derived Oncogenes and Tumor Suppressors
Jee H, Park E, Hur K, Kang M, Kim Y |
Frontiers in Molecular Biosciences | 2022 |
Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells
Tan GM, Poudel A, Ali Hosseini Rad SM, McLellan AD |
Cancers | 2022 |
AKT Isoforms in the Immune Response in Cancer.
Ahmad Z, Somanath PR |
Current topics in microbiology and immunology | 2022 |
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
Maldonado-Pérez N, Tristán-Manzano M, Justicia-Lirio P, Martínez-Planes E, Muñoz P, Pavlovic K, Cortijo-Gutiérrez M, Blanco-Benítez C, Castella M, Juan M, Wenes M, Romero P, Molina-Estévez FJ, Marañón C, Herrera C, Benabdellah K, Martin F |
Frontiers in immunology | 2022 |
Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
Li F, Zhao S, Wei C, Hu Y, Xu T, Xin X, Zhu T, Shang L, Ke S, Zhou J, Xu X, Gao Y, Zhao A, Gao J |
Frontiers in immunology | 2022 |
Challenges of COPD Patients during the COVID-19 Pandemic
Sun SW, Qi C, Xiong XZ |
Pathogens | 2022 |